Guazzelli, A.; Meysami, P.; Bakker, E.; Demonacos, C.; Giordano, A.; Krstic-Demonacos, M.; Mutti, L.
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. Int. J. Mol. Sci. 2019, 20, 429.
https://doi.org/10.3390/ijms20020429
AMA Style
Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, Mutti L.
BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. International Journal of Molecular Sciences. 2019; 20(2):429.
https://doi.org/10.3390/ijms20020429
Chicago/Turabian Style
Guazzelli, Alice, Parisa Meysami, Emyr Bakker, Constantinos Demonacos, Antonio Giordano, Marija Krstic-Demonacos, and Luciano Mutti.
2019. "BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment" International Journal of Molecular Sciences 20, no. 2: 429.
https://doi.org/10.3390/ijms20020429
APA Style
Guazzelli, A., Meysami, P., Bakker, E., Demonacos, C., Giordano, A., Krstic-Demonacos, M., & Mutti, L.
(2019). BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment. International Journal of Molecular Sciences, 20(2), 429.
https://doi.org/10.3390/ijms20020429